Literature DB >> 11166375

Interferon-beta1a administration results in a transient increase of serum amyloid A protein and C-reactive protein: comparison with other markers of inflammation.

M T Boylan1, A D Crockard, M E Duddy, M A Armstrong, S A McMillan, S A Hawkins.   

Abstract

Putative markers of inflammation such as serum beta2-microglobulin and neopterin have been shown to be transiently upregulated following interferon-beta (IFN-beta) administration to multiple sclerosis (MS) patients. However, to date the role of the important inflammatory mediators serum amyloid A protein (SAA) and C-reactive protein (CRP) have not been described. Here we show that SAA but not CRP is elevated in relapsing-remitting MS patients compared to normal healthy individuals, and furthermore that both are transiently upregulated following intramuscular injection with IFN-beta1a (Avonex). This pattern of expression was found to parallel that of beta2-microglobulin and neopterin following injection and was mirrored by a selective activation of peripheral monocytes with respect to upregulation of receptors known to be involved in the inflammatory response (HLA-DR, CD16 and CD86). Injection of saline solution intramuscularly to six healthy control individuals did not produce a similar upregulation of any of the inflammatory markers investigated. Following IFN-beta1a injection, all inflammatory responses were attenuated at week 12 of therapy in comparison to those following the initial injection in a group of follow-up patients. In addition, IFN-beta1a injected on a weekly basis did not produce a sustained modulation of any of the markers investigated in patients treated for 32 weeks.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11166375     DOI: 10.1016/s0165-2478(00)00310-2

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  7 in total

1.  IFNs Reset the Differential Capacity of Human Monocyte Subsets to Produce IL-12 in Response to Microbial Stimulation.

Authors:  Alice Muglia Amancio; Lara Mittereder; Alexie Carletti; Kevin W Tosh; Daniel Green; Lis R Antonelli; Ricardo T Gazzinelli; Alan Sher; Dragana Jankovic
Journal:  J Immunol       Date:  2021-02-24       Impact factor: 5.422

2.  Rapid exacerbation of multiple sclerosis following the initiation of interferon-β: report of nine cases.

Authors:  Masoud Etemadifar; Amir Hossein Sarrami
Journal:  J Res Med Sci       Date:  2011-12       Impact factor: 1.852

3.  Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients.

Authors:  Valentina Durastanti; Alessandra Lugaresi; Placido Bramanti; Mariapia Amato; Paolo Bellantonio; Giovanna De Luca; Orietta Picconi; Roberta Fantozzi; Laura Locatelli; Annalisa Solda'; Edoardo Sessa; Rocco Totaro; Silvia Marino; Valentina Zipoli; Marino Zorzon; Enrico Millefiorini
Journal:  J Transl Med       Date:  2011-04-18       Impact factor: 5.531

Review 4.  Human endogenous retroviruses and multiple sclerosis: innocent bystanders or disease determinants?

Authors:  Joseph M Antony; Andre M Deslauriers; Rakesh K Bhat; Kristofer K Ellestad; Christopher Power
Journal:  Biochim Biophys Acta       Date:  2010-08-06

Review 5.  An evaluation of the recognised systemic inflammatory biomarkers of chronic sub-optimal inflammation provides evidence for inflammageing (IFA) during multiple sclerosis (MS).

Authors:  Christopher Bolton
Journal:  Immun Ageing       Date:  2021-04-14       Impact factor: 6.400

6.  Helicobacter pylori VacA suppresses Lactobacillus acidophilus-induced interferon beta signaling in macrophages via alterations in the endocytic pathway.

Authors:  Gudrun Weiss; Sam Forster; Aaron Irving; Michelle Tate; Richard L Ferrero; Paul Hertzog; Hanne Frøkiær; Maria Kaparakis-Liaskos
Journal:  MBio       Date:  2013-06-11       Impact factor: 7.867

7.  Proteomic analysis of cerebrospinal fluid in a fulminant case of multiple sclerosis.

Authors:  Judit Füvesi; Jörg Hanrieder; Krisztina Bencsik; Cecilia Rajda; S Krisztián Kovács; László Kaizer; Sándor Beniczky; László Vécsei; Jonas Bergquist
Journal:  Int J Mol Sci       Date:  2012-06-21       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.